National Comprehensive Cancer Network

Members Only
NCCN Oncology Research Program (ORP)
NCCN ORP Recent News
NCCN ORP Affiliate Research Consortium
NCCN ORP Scientific Publications
NCCN ORP for Industry
NCCN ORP Investigator Steering Committee
NCCN ORP Testimonials
NCCN Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
NCCN Informed Consent Language Database
NCCN Specialized Imaging Research Consortium™ (SIRC)
NCCN ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Bibliography: NCCN Oncology Outcomes Database Abstracts

General:

Niland, JC, Rouse, L, Corona, M, et al. The National Comprehensive Cancer Network (NCCN) Internet-based Outcomes Database System. Academy Health Annual Research Meeting Abstracts. 2006.

Breast Cancer:

Arvold ND, Punglia RS, Hughes ME, et al. Pathologic Characteristics of Second Breast Cancers (SBC) Among Women Previously Treated for Ductal Carcinoma in Situ (DCIS) with Breast Conservation. ASCO, 2011.

Vandergrift JL, Niland JC, Theriault RC, et al. Timing in adjuvant chemotherapy (CTX) initiation among women with breast cancer (BC) at National Comprehensive Cancer Network (NCCN) centers: An analysis from the NCCN Outcomes Database. ASCO, 2011.

Hassett MJ, Niland JC, Hughes ME, et al. Gene expression profile testing for breast cancer: Patterns and predictors of use and impact on chemotherapy. Journal of Clinical Oncology (Meeting Abstracts). 2010;28:566-.

Partridge AH, Hughes ME, Wong Y, et al. The effect of age on delay in diagnosis and stage of breast cancer. Journal of Clinical Oncology (Meeting Abstracts). 2010;28:1580-.

Brewster AM, Etzel C, Zhou R, et al. The impact of obesity on adherence to the National Comprehensive Cancer Network (NCCN) guidelines recommending chemotherapy for patients with operable breast cancer. Journal of Clinical Oncology (Meeting Abstracts). 2009;27:6517-.

Hassett MJ, Weeks JC. Identifying high-priority quality measures for breast cancer quality improvement using data from a nationally representative sample. Journal of Clinical Oncology (Meeting Abstracts). 2009;27:6507-.

Hughes ME, Ottesen R, Niland JC, et al. Quality of breast cancer care in NCCN centers as assessed by the ASCO/NCCN quality measures: Overall performance and reasons for nonconcordance. Journal of Clinical Oncology (Meeting Abstracts). 2009;27:6506-.

Lin NU, Vanderplas A, Hughes ME, et al. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). Journal of Clinical Oncology (Meeting Abstracts). 2009;27:543-.

Alderman AK, Collins ED, Schott A, et al. How does reconstructive surgery impact he timing of chemotheray for breast cancer? Results from the National Comprehensive Cancer Center.  Annual American Association of Plastic Surgeons Meeting. 2008; 27.

Greenberg CC, Hughes ME, Lipsitz SR, et al. Insitutional variation in the surgical treatment of early-stage breast cancer. ASCO Breast Cancer Symposium. 2008; 133.

Wong Y, Ottesen R, Niland J, et al. Continued use of trastuzumab (TRZ) beyond disease progression in the National Comprehensive Cancer Network (NCCN). Journal of Clinical Oncology (Meeting Abstracts). 2008;26:6522-.

Hassett MJ, Hughes ME, Niland JC, et al. Chemotherapy use for hormone receptor-positive, node-negative breast cancer. Journal of Clinical Oncology (Meeting Abstracts). 2007;25:11004-.

Hassett MJ, Hughes ME, Niland JC, et al.  Identifying Quality Targets for Breast Cancer Care. Academy Health Annual Research Meeting Abstracts. 2006.

Weeks JC, Niland JC, Hughes JC, et al. Institutional Variation in Concordance with Guidelines for Breast Cancer Care in the National Comprehensive Cancer Network:  Implications for Choice of Quality Indicators. Annual Health Services Research Meeting (Panel Presentation). June 2006.

Yen TW, Kuerer HM, Ottesen RA, Rouse L, et al. Impact of randomized clinical trial results on the use of tamoxifen (TAM) following breast surgery for ductal carcinoma in situ (DCIS) in the National Comprehensive Cancer Network (NCCN). Annual San Antonio Breast Conference (Meeting Abstract). December 2006.

Edge SB, Ottesen RA, Lepisto EM, et al.  Surgical biopsy to diagnose breast cancer adversely affects outcomes of breast cancer care: Finding from the National Comprehensive Cancer Network. Annual San Antonio Breast Conference (Meeting Abstract). 2005.

Svahn TH, Niland JC, Hughes ME, et al.  Predictors and temporal trends of adjuvant endocrine therapy use in breast cancer.  Annual San Antonio Breast Conference (Meeting Abstract). 2005.

Punglia RS, Hughes ME, Edge SB, et al. Factors associated with appropriate use of radiation therapy after mastectomy in women with Stage I-II breast cancer treated within the National Comprehensive Cancer Network (NCCN). Journal of Clinical Oncology (Meeting Abstracts). 2004;22:6032-.

Punglia RS, Hughes ME, Edge SB, et al. Development and applications of quality measures:  Studying guideline-concordant use of radiation therapy after mastectomy in the National Comprehensive Cancer Network. Annual American Society of Therapeutic Radiology and Oncology Meeting. 2004.

Buchholz TA, Theriault RL, Hughes M, et al.  Patterns of Radiation Use as a Component of Breast Conservation Therapy for Noninvasive and Invasive Breast Cancers in United States National Comprehensive Cancer Network (NCCN) Centers.  The Cancer Journal. 2003; 9(6):485-519. Abstract 38.

Christian C, Edge S, Niland JC, et al.  A multi-institutional analysis of socioeconomic determinants of breast reconstruction.  Annual Meeting of the Association for Academic Surgery. 2003.

Theriault RL, Niland JC, Lepisto EM, et al.  The impact of age on the receipt of guideline-recommended systemic therapy for breast cancer.  Annual NCCN Conference (Meeting Abstract). 2003.

Edge SB, Pass H, Niland JC, et al. Rapid Implementation of Sentinel Node Biopsy for Breast Cancer at Cancer Centers. Journal of Clinical Oncology (Meeting Abstracts). 2001.

Non-Hodgkin's Lymphomas:

Abou-Nassar KE, Vanderplas A, Friedberg JW, et al.  Patterns of use of FDG-PET for the initial staging of follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network (NCCN) Lymphoma Database. ASH Annual Meeting Abstracts. 2010; 116: 81.

Kumar A, Vanderplas A, LaCasce AS, et al.  Incidence, Method and Covariates of Central Nervous System (CNS) Prophylaxis for Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database. ASH Annual Meeting Abstracts. 2010; 116:1756.

Abel GA, Vanderplas A, Friedberg JW, et al. Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database. ASH Annual Meeting Abstracts. 2009;114:1387-.

LaCasce A, Vandergrift JL, Rodriguez MA, et al. R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project. ASH Annual Meeting Abstracts. 2009;114:403-.

Kho ME, Lepisto EM, Niland JC, et al. Reliability of data collection for the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multi-center outcomes database: A methodological approach. Journal of Clinical Oncology (Meeting Abstracts). 2007;25:6525-.

Rodriguez MA, Veer AT, Nademanee A, et al. Concordance with National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines (CPGs): A Quality of Care Tool for Newly Diagnosed Patients (pts) with Mantle Cell Lymphoma (MCL). ASH Annual Meeting Abstracts. 2006;108:3328-.

LaCasce A, Niland J, Kho ME, et al. Potential Impact of Pathologic Review on Therapy in Non-Hodgkin's Lymphoma (NHL): Analysis from the National Comprehensive Cancer Network (NCCN) NHL Outcomes Project. ASH Annual Meeting Abstracts. 2005;106:2816-.

Rodriguez MA, Czuczman MS, Friedberg JW, et al. Age Significantly Influences Presentation and Patterns of Care in Patients with Newly Diagnosed Diffuse Large Cell Lymphoma (DLCL): Collective Data from 5 Centers Participating in the National Comprehensive Center Network (NCCN) NHL Outcomes Project. ASH Annual Meeting Abstracts. 2005;106:1335-.

Friedberg JW, Kho ME, Lepisto EM, et al. Evolution of Rituximab as "Standard" Therapy in Patients (pts) with Newly Diagnosed Follicular (FL), Mantle Cell (MCL), and Diffuse Large B Cell (DLCL) Non-Hodgkin's Lymphoma (NHL) in 5 United States Comprehensive Cancer Centers: An Analysis from the National Comprehensive Cancer Network (NCCN) NHL Outcomes Project. ASH Annual Meeting Abstracts. 2004;104:1391-.

Colon/Rectal Cancer:

Khrizman P,  Niland JC, ter Veer A, et al. Postoperative adjuvant chemotherapy (CTX) use in stage II/III rectal cancer patients (Pts) treated with neoadjuvant therapy: a national comprehensive cancer network (NCCN) analysis. ASCO, 2011.

Earle CC, Weiser MR, Shibata S, et al. Lymph node retrieval rates affect adjuvant chemotherapy (AC) utilization for stage II colon cancer at the National Comprehensive Cancer Network (NCCN) institutions. Journal of Clinical Oncology (Meeting Abstracts). 2008;26:4046-.

Rajput A, Skibber J, Engstrom P, et al. Meeting the 12 lymph nodes (LN) benchmark in colorectal cancer surgery: A comparison of NCCN and SEER data. Journal of Clinical Oncology (Meeting Abstracts). 2007;25:4015-.

Weiser M, Romanus D, terVeer A, et al. Incidence of minimally invasive colorectal cancer (CRC) surgery in patients treated at NCCN institutions. Journal of Clinical Oncology (Meeting Abstracts). 2007;25:6575-.

Non-Small Cell Lung Cancer:

Bickel KE, Niland JC, Mamet R, et al.  Aggressive end-of-life (EOL) chemotherapy (CT) use in metastatic non-small cell lung cancer (mNSCLC): A National Comprehensive Cancer Network (NCCN) Outcomes Database analysis. ASCO, 2011.

Lepisto EM, Vandergrift JL, Kalemkerian GP, et al. Oncology Medication Utilization Based On Federal Drug Administration (FDA) Labeling, National Comprehensive Cancer Network (NCCN) Clinical Practice Guideline (GL) Recommendations, and Evidence for Patients with Advanced Non Small Cell Lung Cancer (NSCLC): An Analysis from the NCCN Oncology Outcomes Database. ISPOR Annual Meeting Abstracts. 2011.

D'Amico TA, Onaitis M, Niland J, et al.  Efficacy of Mediastinal Lymph Node Dissection by Thoracoscopy and Thoracotomy During Lobectomy for Lung Cancer. Society for Thoracic Surgeons Annual Conference Abstracts. 2011.

Ferketich AK, Niland JC, Mamet R, et al.  Survival among Smokers and Nonsmokers in the National Comprehensive Cancer Network (NCCN) Non Small Cell Lung Cancer (NSCLC) Cohort. Chicago Multidisciplinary Symposium in Thoracic Oncology Abstracts. 2010.

Kapadia NS, Mamet R, Zornosa C, et al.  Radiation Therapy (RT) at the End of Life (EOL) in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology. 2010; 78(3), 66-67.

Vandergrift JL, Mamet R, Zornosa C, et al. First-line systemic therapy in metastatic non-small cell lung cancer (mNSCLC) patients treated at National Comprehensive Cancer Network (NCCN) institutions: An analysis from the NCCN Oncology Outcomes Database Project. Journal of Clinical Oncology (Meeting Abstracts). 2010;28:7634-.

Zornosa C, Mamet R, Reid ME, et al. Utilization of adjuvant therapy among completely resected non-small cell lung cancer (NSCLC) patients in the National Comprehensive Cancer Network (NCCN) Outcomes Database Project. Journal of Clinical Oncology (Meeting Abstracts). 2010;28:7017-.